Source comparison
Side-by-Side Comparison
Class GHRP (Growth Hormone Releasing Peptide) GHRH analog (Growth Hormone Releasing Hormone) Mechanism Ghrelin/GHS receptor agonist GHRH receptor agonist Evidence Grade B+ Route Subcutaneous injection Typical Dose 200 - 300 mcg, 2-3x daily 200 - 500 mcg before
This comparison does not assign a generated winner or score.
- Class
- GHRP (Growth Hormone Releasing Peptide)
- GHRH analog (Growth Hormone Releasing Hormone)
- Mechanism
- Ghrelin/GHS receptor agonist
- GHRH receptor agonist
- Evidence Grade
- B+
- Route
- Subcutaneous injection
- Typical Dose
- 200 - 300 mcg, 2-3x daily
- 200 - 500 mcg before bed
- Half-Life
- ~2 hours
- ~10-20 minutes
- GH Pulse Strength
- Strong, consistent pulses
- Moderate, physiological pulses
- Cortisol Impact
- Minimal (selective)
- None
- Prolactin Impact
- Minimal
- Appetite Effect
- Minimal (unlike GHRP-6)
- FDA History
- Not FDA-approved
- Previously FDA-approved (withdrawn 2008, commercial reasons)
- Desensitization Risk
- Low with proper cycling
- Very low
- Best Combined With
- CJC-1295 (GHRH analog)
- Ipamorelin or GHRP-2 (GHRP)
- Cost (research grade)
- $
- $$